|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's range||108.93 - 111.00|
|52-week range||61.28 - 120.23|
|Beta (5Y monthly)||1.19|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||130.74|
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.